Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- LILLY (ELI) & COMPANY - FDA Approves EVISTA to Reduce Risk of Breast Cancer.
- For Release: September 14, 2007 Refer to: Sharon Corbitt Office: (317) 277-1574 Mobile: (317) 997-1206 E-mail: corbittsd@lilly.com FDA Approves Lilly's Osteoporosis Drug EVISTAA[R] raloxifene HCl to Reduce The Risk of Invasive Breast C ...
- Research articles 2007-09-14
- WIN Against Breast Cancer Encouraged by FDA Decision to Issue Approvable Letter to Mentor for Silicone Gel Breast Implants; Decision Means More Options for Women.
- Byline: Women's Information Network Against Breast Cancer Byline: Women's Information Network Against Breast Cancer
- Research articles 2005-07-29
- Apthera Announces Completion of End of Phase II Meeting with the U.S. Food and Drug Administration for NeuVax™ for Breast Cancer
- Company Finalizing Protocols for Phase II/III Registration Study
- Research articles 2007-10-31
- Oncor's Sales of the Inform Test for Breast Cancer to Benefit From FDA Advisory Panel Recommendation to Approve New Treatment Targeting Her-2/neu
- GAITHERSBURG, Md.--BW HealthWire--Sept. 3, 1998--Oncor (AMEX: ONC) announced today that it expects sales of its INFORMR HER-2/neu breast cancer test to benefit from the FDA Advisory Panel's recommendation to approve Genentech's HerceptinR anti-HER-2/neu monoclonal antibody treatment for metastatic breast cancer. Herceptin is the first treatment for an aggressive type of...
- Research articles 1998-09-03
- FDA approve GSK breast cancer drug
- GlaxoSmithKline has received FDA approval for Tykerb lapatinib, in combination with Xeloda capecitabine, for the treatment of advanced or metastatic HER2 (ErbB2)-positive breast cancer in women whose disease has progressed despite treatment with priorGlaxoSmithKline has received FDA approval for Tykerb lapatinib, in combination with Xeloda capecitabine, for the treatment of...
- Research articles 2007-04-01
- Oncor's Sales of the Inform Test for Breast Cancer to Benefit From FDA Advisory Panel Recommendation to Approve New Treatment Targeting Her-2/neu
- GAITHERSBURG, Md.--BW HealthWire--Sept. 3, 1998--Oncor (AMEX: ONC) announced today that it expects sales of its INFORMR HER-2/neu breast cancer test to benefit from the FDA Advisory Panel's recommendation to approve Genentech's HerceptinR anti-HER-2/neu monoclonal antibody treatment for metastatic breast cancer. Herceptin is the first treatment for an aggressive type of...
- Research articles 1998-09-03
- YM BIOSCIENCES INC. - Statement re YM BioSciences receives FDA fast track.
- YM BioSciences receives FDA fast track designation for tesmilifene in advanced breast cancer MISSISSAUGA, Canada, Feb. 13 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), the cancer product development...
- Research articles 2006-02-13
- FDA approves study for breast cancer risk test by InterGenetics of
- The U.S. Food and Drug Administration has approved an investigational device exemption study for a breast cancer risk test developed by InterGenetics of Oklahoma City.
- Research articles 2006-09-20
- Chiron and Ciba announce FDA market clearance of Aredia® for treatment of patients with Osteolytic Bone Metastases of breast cancer; First Therapeutic For Osteolytic Bone Metastases Associated with Breast Cancer
- EMERYVILLE, Calif. and SUMMIT, N.J.--HealthWire--August 12, 1996-- Chiron Therapeutics, a business unit of Chiron Corporation (Nasdaq: CHIR), and Ciba Pharmaceuticals, a division of Ciba-Geigy Corporation jointly announced today that the United States Food and Drug Administration FDA has cleared ArediaR pamidronate disodium for injection for marketing for the treatment of...
- Research articles 1996-08-12
- FDA Advisory Panel Recommends Approval of Zeneca's Nolvadex -Tamoxifen Citrate- for Reduction of Incidence of Breast Cancer in Women At Increased Risk
- WILMINGTON, Del.--BUSINESS WIRE--Sept. 2, 1998--Zeneca Pharmaceuticals said that it is encouraged by today's decision by the U.S. Food and Drug Administration's FDA Oncologic Drugs Advisory Committee ODAC to recommend for approval NOLVADEXR tamoxifen citrate for reduction of the incidence of breast cancer in women at increased risk, as defined by...
- Research articles 1998-09-02
- Arimidex results expand anticancer class. (Markets: Life Sciences).(Brief Article)
- ASTRAZENECA PLC AZ has pulled a stroke ahead of Novartis AG in the race for the $2 billion early breast cancer market. In September, the Food and Drug Administration FDA approved AZ's supplemental new drug application for Arimidex anastrozole ASTRAZENECA PLC AZ has pulled...
- Research articles 2002-09-16
- FDA Approves Expanded Use for Computer Aided Detection Technology for Breast Cancer - CAD
- Business Editors/Health & Medical Writers
- Research articles 2001-06-13
- FDA Advisory Panel Recommends Approval of Zeneca's Nolvadex -Tamoxifen Citrate- for Reduction of Incidence of Breast Cancer in Women At Increased Risk
- WILMINGTON, Del.--BUSINESS WIRE--Sept. 2, 1998--Zeneca Pharmaceuticals said that it is encouraged by today's decision by the U.S. Food and Drug Administration's FDA Oncologic Drugs Advisory Committee ODAC to recommend for approval NOLVADEXR tamoxifen citrate for reduction of the incidence of breast cancer in women at increased risk, as defined by...
- Research articles 1998-09-02
- ImClone Announces Agreement with FDA on Special Protocol Assessment for Phase III Study of IMC-1121B in Breast Cancer
- NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that it has reached agreement with the U.S. Food and Drug Administration FDA under a Special Protocol Assessment SPA for its planned Phase III clinical trial...
- Research articles 2008-04-22
- FDA Clears Breast Cancer-Specific Molecular Prognostic Test
- NEWS BRIEFSNEWS BRIEFS
- Research articles 2007-04-01
- FDA Approves First Gene-Based Test to Detect the Spread of Breast Cancer Into Lymph Nodes
- To: SCIENCE EDITORSTo: SCIENCE EDITORS
- Research articles 2007-07-16
- California Company Gets FDA Approval for Breast Cancer Detection System.
- Knight Ridder/Tribune Business News Knight Ridder/Tribune Business News
- Research articles 1999-07-29
- FDA Approves Drug as Alternative to Chemotherapy for Breast Cancer.
- Knight Ridder/Tribune Business News Knight Ridder/Tribune Business News
- Research articles 1998-04-30
- AstraZeneca Submits New Drug Application to FDA for New Type of Breast Cancer Treatment
- Business Editors/Health & Medical Writers
- Research articles 2001-03-29
- FDA Advisory Committee Unanimously Recommends Approval of Breast Cancer Test to Select Candidates for Herceptin Therapy
- Business Editors/Health & Medical Writers
- Research articles 2001-12-05
- << Previous
- page 1 of 2
- Next >>
